Refine by
Cytology Articles & Analysis
39 articles found
Alfa Cytology has revealed new FAP-targeted therapeutics development services that aim to develop precise and effective cancer treatments. Alfa Cytology has introduced its groundbreaking initiative which targets fibroblast activation protein(FAP) for cancer therapies. ...
Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for its cutting-edge preclinical alfaCAR-T solutions. ...
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. ...
In recent years, the fight against cancer has seen significant advances, particularly with the emergence of targeted therapy. Among the most promising strategies in this domain is the development of radioactive drug conjugates(RDCs). These innovative therapeutic agents combine the targeting capabilities of antibodies with the cytotoxic effects of radioactive isotopes, providing a powerful ...
In the ever-evolving landscape of cancer research, two intriguing concepts have emerged that are reshaping how scientists approach treatment: synthetic lethality and parthanatos. Both concepts encapsulate the complexity of cellular processes and open new avenues for targeted therapies. What is Synthetic Lethality? Synthetic lethality occurs when the simultaneous disruption of two genes ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. ...
Alfa Cytology has launched ovarian cancer therapy development services. Alfa Cytology, a prominent services provider in oncology, has launched its cutting-edge ovarian cancer therapy development services. ...
Alfa Cytology unveils advanced cancer immunotherapy development services. Alfa Cytology, a renowned services supplier in oncology, has recently introduced its groundbreaking cancer immunotherapy development services. ...
Leukemia, a malignant disorder of the blood and bone marrow, poses significant challenges to both patients and healthcare providers. Traditional treatments, including chemotherapy and radiation, while effective for some, often come with severe side effects and varied success rates. Enter immunotherapy - a groundbreaking approach that is not only redefining leukemia treatment but also offering ...
Alfa Cytology introduces comprehensive small molecule PARPi development services for combating various diseases. Alfa Cytology, a developer of oncology innovation, has announced its latest venture small molecule Poly(ADP-ribose) polymerase inhibitor development services. ...
l Feulgen Microdensitometry This classical cytological technique involves staining fixed nuclei with Feulgen reagent, which binds specifically to DNA. ...
This cost-effective, measurable approach delivers reliable insights for breeders. l Cytological Markers: For a deeper examination of chromosome-level variation, Lifeasible offers advanced techniques, including Fluorescence In Situ Hybridization (FISH) and Genomic In Situ Hybridization (GISH). ...
Alfa Cytology has unveiled new services focused on therapeutic antibody development for bladder cancer research.Alfa Cytology, a prominent cancer research services supplier based in New York, proudly announces the launch of its comprehensive services for bladder cancer therapeutic antibody development. ...
Breast cancer remains one of the most prevalent malignancies affecting women worldwide, necessitating innovative approaches for effective treatment and research. Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). These advancements not only enhance our understanding of the disease ...
Bladder cancer, a malignancy that arises in the tissues of the bladder, ranks as the sixth most common cancer in the United States. It presents significant challenges in diagnosis, treatment, and recurrence management. As researchers strive to advance our understanding of this disease, the advantages and importance of bladder cancer animal models are gradually being discovered. The ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. ...
Peptidomimetics are structural analogs of peptides or proteins that mimic their biological activities. They are designed to overcome limitations associated with peptides, such as poor stability and bioavailability by preserving or enhancing their functions. Peptidomimetic development involves the design and synthesis of molecules that mimic three-dimensional structures and functional groups of ...
Alfa Cytology has announced cancer diagnostic biomarker development services to enhance precision in oncology research. ...
Whether pathologic research or therapeutics development, CD BioSciences practically has experienced cytology experts with advanced equipment and tech to accelerate research progress. ...
Cancer is a daunting diagnosis; however, the rapid advancements in oncology are continuously perfecting patient outcomes and quality of life. Among the groundbreaking developments, cancer vaccines are a promising frontier1. These vaccines are transforming how we approach cancer treatment, leveraging the body's immune system to fight malignancies more effectively. To grasp how cancer vaccines ...